Pharmaceuticals
A Pair of Rare Disease Biotech Concerns Worth a Good Look
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
Alexion Higher on Spanish Report, Cited by Analyst, That Amgen Will Make Bid
Mizuho's Salim Syed says talk of possible tieup isn't far-fetched. Alexion and Amgen decline comment.
Endo Surges as Opioid Maker Reaches Settlement in Landmark Lawsuit
Endo's stock price surges after the company announces a settlement with Cuyahoga and Summit counties, removing the company from a potentially damaging trial in state court in October.
How to Extract Pretty Profits from Ugly Stocks
It's a process that involves harvesting gains by repeatedly writing call options against stocks steadily in decline.
Amarin Shares Show Heart as Anti-Cholesterol Drug Firm Bucks Market Rout
Amarin's stock jumped after SVB Leerink upped its rating on the biotech's stock to outperform, saying a recent double-digit decline offers a buying opportunity.
Deciphera Soars on Positive Phase III Drug Trial
Deciphera Pharma stock more than doubled on positive results from a Phase III clinical study of its drug to treat patients with advanced gastrointestinal stromal tumors.
Earnings to Tell Whether Cannabis' High Growth Story Is Going to Pot
After a 2018 high, marijuana stocks are gaining popularity again, but which ones are producing the most green for investors? Here are the charts.
Evolus Could See Breakout Soon
EOLS appears to have formed a small triangle pattern the past few weeks and a breakout is likely before reaching the apex.
CBD-Laced Foods Could Be Technically Illegal, But the FDA Might Soon Change That
Agency has the authority to carve out an exception to existing laws.
Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.